Siglec-12 CRISPR/Cas9 KO Plasmid (h): sc-413805
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Siglec-12 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Siglec-12 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Siglec-12 CRISPR/Cas9 KO Plasmid (h) | sc-413805 | 20 µg | $397.00 |
Overview
SIGLEC12 encodes Siglec-12, an atypical sialic acid–binding immunoglobulin-like lectin expressed in select epithelial and immune contexts and localized to the cell surface. As a member of the Siglec family, Siglec-12 participates in glycan-dependent recognition events that can influence cell–cell interactions, endocytosis, and modulation of signaling outputs downstream of immunoreceptor-associated pathways. The human protein is considered functionally distinct from canonical inhibitory Siglecs due to alterations in conserved motifs, making it a useful model for studying divergence in glyco-immune receptor signaling. Dysregulated Siglec-12 expression has been investigated in the context of tumor biology and inflammatory microenvironments, supporting research into glycosylation-dependent phenotypes and immune–epithelial crosstalk.
Siglec-12 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SIGLEC12 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SIGLEC12 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SIGLEC12 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Siglec-12 protein expression.
This CRISPR knockout system enables efficient generation of SIGLEC12-deficient cell models for investigation of Siglec-12 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SIGLEC12 exon(s) critical for Siglec-12 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SIGLEC12 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Siglec-12 CRISPR/Cas9 KO Plasmid (h) and Siglec-12 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SIGLEC12 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Siglec-12 HDR Plasmid (h) and Siglec-12 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SIGLEC12 homology arms to support homology-directed repair at defined SIGLEC12 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.